Comparing the current results to its competitors, Casi Pharmaceuticals Inc reported Revenue decrease in the 4 quarter 2025 year on year by -27.42 %, despite the revenue increase by the most of its competitors of 10.62 %, recorded in the same quarter.
Casi Pharmaceuticals inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 13.2 %
Casi Pharmaceuticals Inc 's Comment on Competition and Industry Peers
EVOMELA® faces significant competition from generic melphalan products in China, which have reduced its market share. In 2025, one new generic injectable melphalan product entered the market, with three additional generic applications under review by the Center for Drug Evaluation (CDE). These generics, generally priced lower, have increased pricing and marketing pressures, attracting cost-conscious healthcare providers and institutions away from branded products like EVOMELA®. Government-owned hospitals in China restrict drug use to their hospital formularies, making formulary inclusion essential for drug adoption and reimbursement. The company must participate in provincial-level tendering processes to achieve formulary listing; however, winning a tender does not guarantee hospital inclusion. Additionally, EVOMELA® may be included in the National Reimbursement Drug List (NRDL) under China's insurance policy, which automatically covers any drug sharing the same generic name once a competitor's drug is added.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Pyxis Oncology Inc is a biotechnology company focused on developing innovative cancer therapies. Their business model revolves around leveraging novel insights into the immune system to develop a pipeline of potential immunotherapies for cancer treatment. Pyxis Oncology aims to collaborate with strategic partners to advance their therapies through preclinical and clinical development, ultimately aiming to improve patient outcomes in the field of oncology.
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company's revenue streams primarily come from partnerships, licensing agreements, and product sales.
Sources:
Casi Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Casi Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
